Nasus Pharma Ltd Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
Nasus Pharma Ltd (NSRX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -1.75% for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-03-25
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | -1.75% 20-F · filed 2026-03-25 |
| 2024-12-31 | -0.16% 20-F · filed 2026-03-25 |
| 2023-12-31 | -0.85% 20-F · filed 2026-03-25 |